Activate a practice
Make feasibility, documentation, study start-up, and sponsor visibility repeatable.
Infrastructure for clinical development
Clinical development,
with more places to begin.
actiopath is building the infrastructure that lets sponsors transform community care into a durable, trial-ready site network.
$40.6BEstimated U.S. clinical-trial market in 2024
5,318Clinical trials started globally in 2024
1 systemNeeded to connect sponsor demand with community care capacity
The ambition
The site network should not be the bottleneck.
Drug development depends on proving medicines in the real world. Yet the infrastructure to run trials remains concentrated in a relatively small set of experienced sites. The result: sponsors compete for the same capacity while local practices—and their patients—are left outside the system.
actiopath begins by making a single community practice ready for a single study. The larger opportunity is to make every successful activation a reusable piece of clinical-development infrastructure.
Build a network
Turn individual trial-ready sites into a durable source of capacity across studies and sponsors.
Improve the system
Use network-level readiness and performance intelligence to direct the right study to the right community site.
The platform, over time
One operating layer. A compounding advantage.
We are not building another point solution for clinical trials. We are creating the workflow, data, and site relationships that allow a more distributed clinical-development system to operate.
LAYER 01
Site readiness
Feasibility, gap identification, document collection, and startup coordination for research-naïve community practices.
Starting nowLAYER 02
Trial activation
A shared operational record that connects sponsor requirements, site progress, and activation decisions across programs.
NextLAYER 03
Network intelligence
A living view of practice capability, readiness, and performance—so site selection becomes faster and more informed.
FutureA deliberate path
The wedge is narrow. The destination is not.
Enable community practices to participate
Give sponsors a structured way to evaluate and prepare practices that have patients but not a research department.
Make each activation reusable
Retain the readiness record, operating knowledge, and relationships so the next study begins with more capability than the last.
Make access a network property
Give clinical-operations leaders a broader, more transparent supply of sites—across therapeutic areas and study programs.
Why this must change
The supply of patients is not the same as the supply of usable sites.
Community practices can provide care close to where patients live, but participating in research brings a complex set of processes and responsibilities. Sponsors need a model that widens access while preserving the site’s ownership of clinical and regulatory work.
Sources: IQVIA Global Trends in R&D 2025; Grand View Research U.S. Clinical Trials Market; Tufts CSDD site-activation benchmarks.
62%of North American phase II/III sites enrolled at least one patient in 2023.
1,757U.S. emerging-biopharma companies in IQVIA’s 2024 segmentation—an important initial sponsor universe.
actiopath
More trials can begin where care already happens.
Start a conversationFor biotech clinical-operations leaders and chief medical officers.